Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life

Characteristics

N 113

%

Age (median, range)

62 (33–80)

 

ECOG PS (median, range)

1 (0–2)

 

De novo metastatic disease

10

(8.8)

ER status

  

 Positive

87

(77.0)

 Negative

26

(23.0)

PgR status

  

 Positive

72

(63.7)

 Negative

38

(33.6)

 Unk

3

(2.7)

Triple negative

22

(19.5)

HER2 status

  

 Positive

11

(9.7)

 Negative

95

(84.1)

 Unk

7

(6.2)

Neo/adjuvant chemotherapy

82

(72.5)

Adjuvant hormonotherapy

67

(59.3)

Adjuvant trastuzumab

4

(3.5)

Number of prior chemotherapy for advanced disease

  

 1

8

(7.1)

 2

26

(23.0)

 3

34

(30.1)

 4

20

(17.7)

 5

14

(12.4)

 ≥6

11

(9.7)

 Median, range

3 (1–10)

 

Prior hormonotherapy for advanced disease

79

(69.9)

 Median, range

2 (1–5)

 

Number of organs involved

  

 1

17

(15.0)

 2

43

(38.1)

 3

33

(29.2)

 ≥4

20

(17.7)

 Median, range

2 (1–5)

 

Most common metastatic sites

  

 Bone

81

(71.7)

 Liver

60

(53.1)

 Lymph nodes

48

(42.5)

 Lung

36

(31.8)

 Skin

19

(16.8)

 CNS

13

(11.5)

Rechallenge with anthracyclines and/or taxanes

64

(56.6)

  1. ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor 2, CNS central nervous system